Company intelligence / Profile preview

SimulConsult

Chestnut Hill, Massachusetts, United Statessimulconsult.com ↗

Ownership: Private
Development stage: Other

Overview

SimulConsult’s AI-driven diagnostic decision support system has demonstrated significant impact in NIH-funded studies, reducing diagnostic errors by up to 75% when used by physicians. The curated database covers over 9,500 diseases with more than 200,000 relationships between findings and diagnoses. The software supports both clinical workflow and patient engagement through explainable AI tools that generate differential diagnoses and automated documentation.

Therapeutic areas: RheumatologyRare DiseasesNeurology
Modalities: Non-pharmacological therapy (Diagnostic software/AI platform)
Industry: Digital Health Medical Devices

Partnerships

Bioinn Molecular Diagnosis for distribution of NGS tests in Taiwan for neurological/metabolic disorders

Beyond the preview

Go deeper on SimulConsult.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SimulConsult.

Explore the full profile